A new diagnostic paradigm: RNA sequencing from skin offers hope for unexplained gut motility disorders
A study published in Annals of Neurology demonstrates the utility of fibroblast RNA sequencing (RNA-seq) for diagnosing complex neurological disorders, including those presenting with gastrointestinal symptoms like gastroparesis and severe constipation. The research, involving 167 patients with dystonia—a condition often co-occurring with gut motility issues—found that over 80% of disease-associated genes were detectable in skin-derived fibroblasts. The RNA-seq analysis successfully validated the pathogenic effects of genetic variants and provided new diagnoses in nearly 7% of patients where prior genomic sequencing had failed, primarily by identifying cryptic splicing errors in non-coding regions of the genome. This multiomics approach moves beyond DNA analysis to capture functional gene expression and splicing aberrations that are invisible to standard tests.
Why it might matter to you: For gastroenterologists managing complex motility disorders like gastroparesis or chronic intestinal pseudo-obstruction, this research highlights a complementary diagnostic pathway when standard workups are inconclusive. The ability to use a minimally invasive skin biopsy to probe for functional gene defects relevant to the enteric nervous system could refine patient stratification and identify subsets with a monogenic basis. This shift towards integrated multiomics diagnostics may eventually influence clinical algorithms for severe, unexplained GI dysmotility, guiding more personalized management strategies.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
